{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:42:24Z","timestamp":1791229344668,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,26]]},"DOI":"10.7759\/cureus.63181","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T09:16:58Z","timestamp":1719393418000},"source":"Crossref","is-referenced-by-count":1,"title":["Lenalidomide and Dexamethasone in Scleromyxedema: A Case Report of Long-Term Efficacy and Challenges in a 54-Year-Old Patient"],"prefix":"10.7759","author":[{"given":"Supriya","family":"Peshin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani K","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Burwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.111630","article-title":"Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema","volume":"44","author":"Rongioletti F","year":"2001","unstructured":"Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001, 44:273-81. 10.1067\/mjd.2001.111630","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13437","article-title":"Lichen myxedematosus: diagnostic criteria, classification, and severity grading","volume":"56","author":"Nofal A","year":"2017","unstructured":"Nofal A, Amer H, Alakad R, Nofal E, Desouky FE, Yosef A, Albalat W. Lichen myxedematosus: diagnostic criteria, classification, and severity grading. Int J Dermatol. 2017, 56:284-90. 10.1111\/ijd.13437","journal-title":"Int J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.01.007","article-title":"Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients","volume":"69","author":"Rongioletti F","year":"2013","unstructured":"Rongioletti F, Merlo G, Cinotti E, Fausti V, Cozzani E, Cribier B, Metze D. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013, 69:66-72. 10.1016\/j.jaad.2013.01.007","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14244","article-title":"High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system","volume":"31","author":"Guarneri A","year":"2017","unstructured":"Guarneri A, Cioni M, Rongioletti F. High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol. 2017, 31:1157-60. 10.1111\/jdv.14244","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1045002","article-title":"Monoclonal gammopathies of clinical significance (MGCS): in pursuit of optimal treatment","volume":"13","author":"Oganesyan A","year":"2022","unstructured":"Oganesyan A, Gregory A, Malard F, et al.. Monoclonal gammopathies of clinical significance (MGCS): in pursuit of optimal treatment. Front Immunol. 2022, 13:1045002. 10.3389\/fimmu.2022.1045002","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.114","article-title":"Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial","volume":"6","author":"Jones JR","year":"2016","unstructured":"Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016, 6:506. 10.1038\/bcj.2016.114","journal-title":"Blood Cancer J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/260610-lenalidomide-and-dexamethasone-in-scleromyxedema-a-case-report-of-long-term-efficacy-and-challenges-in-a-54-year-old-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T09:17:00Z","timestamp":1719393420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/260610-lenalidomide-and-dexamethasone-in-scleromyxedema-a-case-report-of-long-term-efficacy-and-challenges-in-a-54-year-old-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.63181","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}